| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psoriasis | 325 | 2021 | 355 | 73.010 |
Why?
|
| Dermatologic Agents | 189 | 2021 | 233 | 44.900 |
Why?
|
| Dermatology | 116 | 2021 | 157 | 25.610 |
Why?
|
| Dermatitis, Atopic | 72 | 2020 | 103 | 20.920 |
Why?
|
| Acne Vulgaris | 75 | 2021 | 101 | 20.580 |
Why?
|
| Skin Diseases | 85 | 2021 | 135 | 18.800 |
Why?
|
| Medication Adherence | 73 | 2020 | 160 | 18.360 |
Why?
|
| Biological Products | 47 | 2021 | 79 | 14.820 |
Why?
|
| Humans | 819 | 2021 | 32271 | 14.360 |
Why?
|
| Rosacea | 38 | 2019 | 46 | 14.330 |
Why?
|
| Antibodies, Monoclonal | 44 | 2020 | 245 | 10.020 |
Why?
|
| Glucocorticoids | 39 | 2019 | 146 | 9.670 |
Why?
|
| Severity of Illness Index | 130 | 2020 | 854 | 9.430 |
Why?
|
| Anti-Inflammatory Agents | 39 | 2020 | 99 | 9.360 |
Why?
|
| Patient Compliance | 47 | 2020 | 206 | 9.160 |
Why?
|
| Skin Neoplasms | 45 | 2020 | 220 | 8.210 |
Why?
|
| Ultraviolet Therapy | 34 | 2019 | 37 | 8.010 |
Why?
|
| United States | 197 | 2021 | 4069 | 7.580 |
Why?
|
| Phototherapy | 35 | 2020 | 50 | 7.510 |
Why?
|
| Quality of Life | 80 | 2021 | 969 | 7.130 |
Why?
|
| Physician-Patient Relations | 38 | 2019 | 179 | 7.100 |
Why?
|
| Treatment Outcome | 135 | 2021 | 3408 | 7.100 |
Why?
|
| Administration, Topical | 84 | 2020 | 142 | 7.060 |
Why?
|
| Administration, Cutaneous | 75 | 2020 | 116 | 7.060 |
Why?
|
| Adrenal Cortex Hormones | 30 | 2020 | 115 | 6.890 |
Why?
|
| Adult | 249 | 2021 | 9260 | 6.860 |
Why?
|
| Anti-Bacterial Agents | 35 | 2020 | 324 | 6.780 |
Why?
|
| Skin | 29 | 2020 | 212 | 6.700 |
Why?
|
| Female | 320 | 2021 | 19943 | 6.660 |
Why?
|
| Health Care Costs | 34 | 2020 | 122 | 6.570 |
Why?
|
| Male | 306 | 2021 | 19437 | 6.520 |
Why?
|
| Patient Satisfaction | 37 | 2020 | 230 | 6.350 |
Why?
|
| Middle Aged | 224 | 2021 | 11838 | 6.140 |
Why?
|
| Health Care Surveys | 60 | 2020 | 184 | 5.940 |
Why?
|
| Patient Education as Topic | 34 | 2019 | 245 | 5.790 |
Why?
|
| Office Visits | 39 | 2017 | 71 | 5.480 |
Why?
|
| Adolescent | 136 | 2020 | 3516 | 5.350 |
Why?
|
| Retinoids | 27 | 2019 | 42 | 5.280 |
Why?
|
| Ambulatory Care | 33 | 2018 | 111 | 5.100 |
Why?
|
| Desoximetasone | 10 | 2020 | 10 | 5.030 |
Why?
|
| Clobetasol | 21 | 2020 | 26 | 5.000 |
Why?
|
| Young Adult | 88 | 2020 | 2651 | 4.560 |
Why?
|
| Immunosuppressive Agents | 29 | 2020 | 248 | 4.510 |
Why?
|
| Methotrexate | 28 | 2020 | 70 | 4.410 |
Why?
|
| Calcitriol | 18 | 2020 | 29 | 4.340 |
Why?
|
| Practice Guidelines as Topic | 32 | 2020 | 395 | 4.290 |
Why?
|
| Immunologic Factors | 22 | 2021 | 53 | 4.250 |
Why?
|
| Clinical Trials as Topic | 39 | 2019 | 312 | 4.050 |
Why?
|
| Benzoyl Peroxide | 16 | 2021 | 20 | 3.980 |
Why?
|
| Keratolytic Agents | 24 | 2018 | 29 | 3.900 |
Why?
|
| Drug Costs | 22 | 2020 | 46 | 3.790 |
Why?
|
| Keratosis, Actinic | 11 | 2021 | 20 | 3.680 |
Why?
|
| Arthritis, Psoriatic | 20 | 2019 | 24 | 3.620 |
Why?
|
| Acitretin | 17 | 2018 | 18 | 3.620 |
Why?
|
| Dermatitis, Allergic Contact | 10 | 2019 | 14 | 3.580 |
Why?
|
| Aged | 134 | 2021 | 10249 | 3.570 |
Why?
|
| Child | 85 | 2020 | 2431 | 3.560 |
Why?
|
| Drug Prescriptions | 17 | 2017 | 54 | 3.350 |
Why?
|
| Health Expenditures | 11 | 2020 | 66 | 3.250 |
Why?
|
| Internship and Residency | 12 | 2019 | 317 | 3.070 |
Why?
|
| Betamethasone | 12 | 2020 | 53 | 3.020 |
Why?
|
| Internet | 17 | 2019 | 202 | 2.920 |
Why?
|
| Retrospective Studies | 67 | 2020 | 3609 | 2.920 |
Why?
|
| Erythema | 11 | 2019 | 25 | 2.860 |
Why?
|
| Cost-Benefit Analysis | 38 | 2018 | 191 | 2.760 |
Why?
|
| Nicotinic Acids | 7 | 2020 | 8 | 2.710 |
Why?
|
| Depression | 17 | 2021 | 427 | 2.680 |
Why?
|
| Drug Monitoring | 14 | 2019 | 30 | 2.510 |
Why?
|
| Pruritus | 14 | 2020 | 46 | 2.500 |
Why?
|
| Ultraviolet Rays | 16 | 2020 | 48 | 2.490 |
Why?
|
| Randomized Controlled Trials as Topic | 28 | 2021 | 545 | 2.460 |
Why?
|
| Boron Compounds | 6 | 2020 | 11 | 2.450 |
Why?
|
| Drug Therapy, Combination | 33 | 2019 | 292 | 2.450 |
Why?
|
| Biological Factors | 7 | 2020 | 10 | 2.430 |
Why?
|
| Drug Utilization | 15 | 2018 | 44 | 2.360 |
Why?
|
| Thalidomide | 7 | 2019 | 32 | 2.340 |
Why?
|
| Immunoglobulin G | 20 | 2013 | 129 | 2.340 |
Why?
|
| Facial Dermatoses | 9 | 2019 | 18 | 2.340 |
Why?
|
| Patient Acceptance of Health Care | 11 | 2020 | 158 | 2.320 |
Why?
|
| Cost of Illness | 17 | 2020 | 72 | 2.310 |
Why?
|
| Insurance, Health | 12 | 2020 | 95 | 2.280 |
Why?
|
| Communication | 11 | 2019 | 129 | 2.280 |
Why?
|
| Patient Preference | 13 | 2019 | 48 | 2.220 |
Why?
|
| Self Care | 10 | 2019 | 97 | 2.220 |
Why?
|
| Home Care Services | 7 | 2020 | 51 | 2.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2019 | 215 | 2.170 |
Why?
|
| Naphthalenes | 8 | 2021 | 53 | 2.170 |
Why?
|
| Administration, Oral | 25 | 2019 | 200 | 2.150 |
Why?
|
| Child, Preschool | 44 | 2020 | 1233 | 2.140 |
Why?
|
| Prevalence | 38 | 2021 | 955 | 2.120 |
Why?
|
| Comorbidity | 23 | 2020 | 563 | 2.090 |
Why?
|
| Databases, Factual | 25 | 2020 | 367 | 2.080 |
Why?
|
| Prescription Drugs | 6 | 2020 | 19 | 2.030 |
Why?
|
| Biological Therapy | 9 | 2020 | 18 | 2.010 |
Why?
|
| Double-Blind Method | 27 | 2021 | 566 | 2.000 |
Why?
|
| Scalp Dermatoses | 6 | 2016 | 18 | 1.960 |
Why?
|
| Sunbathing | 5 | 2018 | 6 | 1.950 |
Why?
|
| Receptors, Tumor Necrosis Factor | 20 | 2013 | 43 | 1.920 |
Why?
|
| Quality of Health Care | 9 | 2018 | 148 | 1.890 |
Why?
|
| Drug Administration Schedule | 27 | 2019 | 276 | 1.850 |
Why?
|
| Ambulatory Surgical Procedures | 12 | 2013 | 26 | 1.820 |
Why?
|
| Antirheumatic Agents | 12 | 2020 | 28 | 1.820 |
Why?
|
| Oxymetazoline | 4 | 2019 | 4 | 1.780 |
Why?
|
| PUVA Therapy | 19 | 2017 | 22 | 1.770 |
Why?
|
| Publishing | 4 | 2020 | 66 | 1.750 |
Why?
|
| Anti-Infective Agents | 7 | 2017 | 35 | 1.720 |
Why?
|
| Drug Design | 8 | 2020 | 51 | 1.710 |
Why?
|
| Biopsy | 8 | 2019 | 249 | 1.670 |
Why?
|
| Interleukin-17 | 5 | 2019 | 26 | 1.670 |
Why?
|
| Tretinoin | 8 | 2014 | 33 | 1.650 |
Why?
|
| Agricultural Workers' Diseases | 15 | 2013 | 36 | 1.640 |
Why?
|
| Eczema | 7 | 2020 | 14 | 1.620 |
Why?
|
| Drug Combinations | 17 | 2021 | 102 | 1.610 |
Why?
|
| Age Factors | 31 | 2020 | 1178 | 1.610 |
Why?
|
| Risk Assessment | 27 | 2019 | 1423 | 1.600 |
Why?
|
| Hand Dermatoses | 6 | 2010 | 10 | 1.570 |
Why?
|
| Pyrroles | 8 | 2018 | 59 | 1.570 |
Why?
|
| Pyrimidines | 8 | 2018 | 77 | 1.550 |
Why?
|
| Metronidazole | 8 | 2017 | 14 | 1.530 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2018 | 28 | 1.510 |
Why?
|
| Sunscreening Agents | 6 | 2020 | 12 | 1.490 |
Why?
|
| Medicare | 19 | 2020 | 218 | 1.470 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2019 | 65 | 1.450 |
Why?
|
| Aged, 80 and over | 37 | 2020 | 3893 | 1.450 |
Why?
|
| Lymphoma | 5 | 2018 | 37 | 1.440 |
Why?
|
| Periodicals as Topic | 5 | 2020 | 90 | 1.430 |
Why?
|
| Time Factors | 27 | 2020 | 2203 | 1.430 |
Why?
|
| Isotretinoin | 7 | 2014 | 13 | 1.400 |
Why?
|
| Pain | 10 | 2020 | 302 | 1.390 |
Why?
|
| Evidence-Based Medicine | 18 | 2021 | 212 | 1.380 |
Why?
|
| Skin Care | 5 | 2019 | 12 | 1.370 |
Why?
|
| Fluorouracil | 4 | 2020 | 79 | 1.350 |
Why?
|
| Pediatrics | 9 | 2020 | 156 | 1.340 |
Why?
|
| Bibliometrics | 3 | 2020 | 11 | 1.330 |
Why?
|
| Drug Industry | 5 | 2019 | 16 | 1.320 |
Why?
|
| Cosmetic Techniques | 4 | 2018 | 11 | 1.310 |
Why?
|
| Pyoderma Gangrenosum | 4 | 2017 | 12 | 1.310 |
Why?
|
| Physician's Role | 6 | 2017 | 41 | 1.310 |
Why?
|
| Infant | 28 | 2020 | 1010 | 1.300 |
Why?
|
| Carcinoma, Basal Cell | 10 | 2015 | 27 | 1.300 |
Why?
|
| Cyclosporine | 11 | 2020 | 48 | 1.270 |
Why?
|
| Piperidines | 8 | 2018 | 137 | 1.250 |
Why?
|
| Caregivers | 6 | 2019 | 114 | 1.240 |
Why?
|
| Sex Factors | 21 | 2020 | 656 | 1.230 |
Why?
|
| Tacrolimus | 8 | 2018 | 66 | 1.220 |
Why?
|
| Goals | 2 | 2020 | 34 | 1.220 |
Why?
|
| Gels | 11 | 2017 | 31 | 1.220 |
Why?
|
| Mohs Surgery | 9 | 2020 | 16 | 1.210 |
Why?
|
| Ethnic Groups | 8 | 2020 | 450 | 1.200 |
Why?
|
| Small Molecule Libraries | 3 | 2017 | 9 | 1.190 |
Why?
|
| Patient Selection | 9 | 2015 | 272 | 1.190 |
Why?
|
| Tuberculosis | 5 | 2020 | 17 | 1.190 |
Why?
|
| Interleukin-23 Subunit p19 | 2 | 2019 | 10 | 1.180 |
Why?
|
| Registries | 8 | 2021 | 294 | 1.180 |
Why?
|
| Fingers | 3 | 2019 | 75 | 1.170 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2013 | 120 | 1.160 |
Why?
|
| Hyperlipidemias | 3 | 2018 | 61 | 1.160 |
Why?
|
| Triamcinolone | 5 | 2018 | 12 | 1.160 |
Why?
|
| Clindamycin | 4 | 2014 | 21 | 1.150 |
Why?
|
| Cross-Sectional Studies | 28 | 2020 | 1480 | 1.140 |
Why?
|
| Salicylic Acid | 5 | 2013 | 6 | 1.130 |
Why?
|
| Wound Healing | 7 | 2018 | 184 | 1.130 |
Why?
|
| Transients and Migrants | 17 | 2013 | 197 | 1.100 |
Why?
|
| Health Resources | 3 | 2018 | 32 | 1.090 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2018 | 37 | 1.090 |
Why?
|
| Dermatitis | 9 | 2019 | 20 | 1.090 |
Why?
|
| Delivery of Health Care | 8 | 2017 | 167 | 1.090 |
Why?
|
| Drug Packaging | 3 | 2020 | 6 | 1.090 |
Why?
|
| Lasers, Excimer | 4 | 2012 | 7 | 1.080 |
Why?
|
| Behavior, Addictive | 4 | 2009 | 40 | 1.080 |
Why?
|
| Animals | 27 | 2020 | 8196 | 1.080 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2015 | 156 | 1.070 |
Why?
|
| Vitamin D | 8 | 2020 | 186 | 1.070 |
Why?
|
| Keratosis | 7 | 2016 | 22 | 1.040 |
Why?
|
| Foot Dermatoses | 5 | 2009 | 8 | 1.040 |
Why?
|
| Primary Health Care | 6 | 2017 | 232 | 1.030 |
Why?
|
| Physicians | 9 | 2018 | 163 | 1.020 |
Why?
|
| Doxycycline | 4 | 2017 | 26 | 1.010 |
Why?
|
| Dermatitis, Contact | 6 | 2014 | 8 | 1.010 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2019 | 716 | 1.010 |
Why?
|
| Attitude of Health Personnel | 5 | 2014 | 183 | 1.010 |
Why?
|
| Antifungal Agents | 5 | 2015 | 44 | 1.000 |
Why?
|
| Patient Care Planning | 3 | 2020 | 55 | 0.990 |
Why?
|
| Hypothyroidism | 2 | 2016 | 10 | 0.990 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 98 | 0.990 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 95 | 0.990 |
Why?
|
| Hispanic Americans | 21 | 2014 | 772 | 0.980 |
Why?
|
| Melanoma | 8 | 2017 | 166 | 0.980 |
Why?
|
| Biomedical Research | 4 | 2019 | 178 | 0.970 |
Why?
|
| Dermatitis, Occupational | 5 | 2019 | 6 | 0.960 |
Why?
|
| Reminder Systems | 2 | 2018 | 23 | 0.960 |
Why?
|
| Medicine | 7 | 2020 | 36 | 0.960 |
Why?
|
| Ointments | 13 | 2020 | 23 | 0.940 |
Why?
|
| Melanosis | 7 | 2010 | 14 | 0.930 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2017 | 316 | 0.930 |
Why?
|
| Models, Economic | 8 | 2018 | 18 | 0.920 |
Why?
|
| Emollients | 8 | 2017 | 11 | 0.910 |
Why?
|
| Fluocinonide | 5 | 2019 | 11 | 0.910 |
Why?
|
| Cardiovascular Diseases | 8 | 2018 | 1159 | 0.910 |
Why?
|
| Onychomycosis | 4 | 2019 | 6 | 0.910 |
Why?
|
| Ivermectin | 4 | 2018 | 9 | 0.910 |
Why?
|
| Insurance Coverage | 7 | 2017 | 80 | 0.900 |
Why?
|
| Dicarboxylic Acids | 4 | 2017 | 6 | 0.890 |
Why?
|
| Hyperpigmentation | 4 | 2018 | 17 | 0.890 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2018 | 90 | 0.880 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2017 | 7 | 0.880 |
Why?
|
| Beauty Culture | 5 | 2009 | 7 | 0.880 |
Why?
|
| Hospitalization | 11 | 2020 | 475 | 0.880 |
Why?
|
| Drug Compounding | 8 | 2019 | 36 | 0.880 |
Why?
|
| Managed Care Programs | 8 | 2014 | 43 | 0.870 |
Why?
|
| Photography | 4 | 2020 | 42 | 0.860 |
Why?
|
| Prednisone | 4 | 2012 | 69 | 0.850 |
Why?
|
| Scalp | 5 | 2020 | 35 | 0.850 |
Why?
|
| Specialties, Surgical | 3 | 2013 | 26 | 0.850 |
Why?
|
| Placebo Effect | 4 | 2017 | 18 | 0.850 |
Why?
|
| Cicatrix | 3 | 2015 | 39 | 0.840 |
Why?
|
| Telemedicine | 4 | 2021 | 122 | 0.840 |
Why?
|
| Utilization Review | 2 | 2019 | 17 | 0.840 |
Why?
|
| Tetracycline | 4 | 2014 | 12 | 0.840 |
Why?
|
| Off-Label Use | 6 | 2020 | 14 | 0.840 |
Why?
|
| Combined Modality Therapy | 15 | 2019 | 551 | 0.830 |
Why?
|
| Continental Population Groups | 4 | 2020 | 228 | 0.830 |
Why?
|
| Health Promotion | 3 | 2018 | 242 | 0.830 |
Why?
|
| Hot Temperature | 5 | 2014 | 81 | 0.830 |
Why?
|
| Health Services Accessibility | 5 | 2017 | 242 | 0.830 |
Why?
|
| Nonprescription Drugs | 5 | 2015 | 18 | 0.830 |
Why?
|
| Depressive Disorder | 3 | 2018 | 69 | 0.830 |
Why?
|
| Treatment Refusal | 4 | 2007 | 14 | 0.820 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2020 | 27 | 0.820 |
Why?
|
| Allergens | 2 | 2019 | 14 | 0.820 |
Why?
|
| Risk | 4 | 2018 | 305 | 0.810 |
Why?
|
| Pharmaceutical Preparations | 2 | 2019 | 38 | 0.810 |
Why?
|
| Follow-Up Studies | 20 | 2018 | 2238 | 0.810 |
Why?
|
| Risk Factors | 26 | 2021 | 3933 | 0.800 |
Why?
|
| Interleukin-23 | 4 | 2019 | 21 | 0.800 |
Why?
|
| Medicaid | 9 | 2020 | 101 | 0.800 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 2 | 2019 | 10 | 0.790 |
Why?
|
| Attitude to Health | 6 | 2019 | 137 | 0.790 |
Why?
|
| Vasoconstriction | 4 | 2017 | 42 | 0.780 |
Why?
|
| Pathology | 3 | 2009 | 20 | 0.780 |
Why?
|
| Disease Management | 5 | 2018 | 129 | 0.780 |
Why?
|
| Monitoring, Physiologic | 3 | 2020 | 77 | 0.770 |
Why?
|
| Laser Therapy | 7 | 2019 | 51 | 0.770 |
Why?
|
| Cost Control | 3 | 2020 | 17 | 0.770 |
Why?
|
| Dermoscopy | 2 | 2013 | 12 | 0.770 |
Why?
|
| Burns | 2 | 2014 | 101 | 0.770 |
Why?
|
| Azetidines | 2 | 2020 | 11 | 0.760 |
Why?
|
| Counseling | 3 | 2020 | 94 | 0.760 |
Why?
|
| Reimbursement, Incentive | 2 | 2015 | 16 | 0.760 |
Why?
|
| Video Recording | 2 | 2013 | 61 | 0.750 |
Why?
|
| Sickness Impact Profile | 9 | 2015 | 39 | 0.740 |
Why?
|
| Tetracyclines | 2 | 2019 | 2 | 0.740 |
Why?
|
| Sulfonamides | 2 | 2020 | 86 | 0.740 |
Why?
|
| Research Design | 7 | 2015 | 316 | 0.740 |
Why?
|
| Vitiligo | 3 | 2019 | 4 | 0.730 |
Why?
|
| Quality Assurance, Health Care | 3 | 2009 | 72 | 0.730 |
Why?
|
| Surgery, Plastic | 5 | 2013 | 29 | 0.720 |
Why?
|
| Hypertension | 3 | 2018 | 980 | 0.720 |
Why?
|
| Ethics, Medical | 2 | 2020 | 21 | 0.720 |
Why?
|
| Drugs, Generic | 5 | 2020 | 14 | 0.710 |
Why?
|
| Vasoconstrictor Agents | 2 | 2019 | 62 | 0.710 |
Why?
|
| Treatment Failure | 8 | 2018 | 164 | 0.710 |
Why?
|
| Autoimmune Diseases | 3 | 2018 | 46 | 0.710 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 47 | 0.700 |
Why?
|
| Obesity | 9 | 2018 | 1111 | 0.700 |
Why?
|
| Equipment and Supplies | 2 | 2020 | 15 | 0.700 |
Why?
|
| Prescription Fees | 2 | 2016 | 5 | 0.700 |
Why?
|
| Petrolatum | 2 | 2020 | 4 | 0.700 |
Why?
|
| Adolescent Behavior | 2 | 2020 | 64 | 0.700 |
Why?
|
| United States Food and Drug Administration | 7 | 2019 | 52 | 0.680 |
Why?
|
| Cryosurgery | 4 | 2015 | 25 | 0.680 |
Why?
|
| Inflammation | 4 | 2019 | 507 | 0.680 |
Why?
|
| Education, Distance | 1 | 2021 | 18 | 0.680 |
Why?
|
| Pilot Projects | 11 | 2018 | 554 | 0.680 |
Why?
|
| Budgets | 2 | 2018 | 10 | 0.680 |
Why?
|
| Surgical Procedures, Operative | 5 | 2010 | 79 | 0.670 |
Why?
|
| Antiviral Agents | 3 | 2020 | 107 | 0.670 |
Why?
|
| Clinical Clerkship | 1 | 2021 | 39 | 0.670 |
Why?
|
| Self Concept | 5 | 2015 | 45 | 0.660 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 4 | 0.660 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2017 | 43 | 0.660 |
Why?
|
| Tattooing | 2 | 2011 | 6 | 0.660 |
Why?
|
| Specialization | 6 | 2017 | 30 | 0.660 |
Why?
|
| Sleep | 2 | 2013 | 87 | 0.650 |
Why?
|
| Incidence | 13 | 2021 | 1242 | 0.650 |
Why?
|
| Plant Extracts | 2 | 2018 | 61 | 0.650 |
Why?
|
| North Carolina | 23 | 2017 | 1300 | 0.650 |
Why?
|
| Forehead | 1 | 2020 | 11 | 0.640 |
Why?
|
| Aerosols | 2 | 2020 | 15 | 0.640 |
Why?
|
| Phobic Disorders | 1 | 2020 | 10 | 0.640 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2020 | 19 | 0.640 |
Why?
|
| Gentian Violet | 1 | 2020 | 3 | 0.640 |
Why?
|
| Medication Errors | 4 | 2009 | 21 | 0.640 |
Why?
|
| Immunotherapy | 2 | 2018 | 91 | 0.640 |
Why?
|
| Professional Practice | 3 | 2011 | 26 | 0.640 |
Why?
|
| Warts | 1 | 2020 | 3 | 0.630 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 16 | 0.630 |
Why?
|
| Back | 1 | 2020 | 4 | 0.630 |
Why?
|
| Social Conformity | 1 | 2020 | 1 | 0.630 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 104 | 0.630 |
Why?
|
| Baths | 1 | 2020 | 6 | 0.630 |
Why?
|
| Cultural Diversity | 1 | 2020 | 17 | 0.630 |
Why?
|
| Infant, Newborn | 13 | 2020 | 666 | 0.620 |
Why?
|
| Impetigo | 2 | 2012 | 4 | 0.620 |
Why?
|
| Multivariate Analysis | 14 | 2015 | 650 | 0.610 |
Why?
|
| Affect | 3 | 2011 | 75 | 0.610 |
Why?
|
| Safety Management | 3 | 2010 | 27 | 0.610 |
Why?
|
| Balsams | 1 | 2019 | 1 | 0.610 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2019 | 1 | 0.610 |
Why?
|
| Job Application | 1 | 2019 | 6 | 0.610 |
Why?
|
| Pigmentation Disorders | 3 | 2014 | 8 | 0.610 |
Why?
|
| Books | 1 | 2019 | 3 | 0.610 |
Why?
|
| Alcoholic Beverages | 1 | 2019 | 5 | 0.610 |
Why?
|
| Patient Care | 3 | 2017 | 28 | 0.610 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2019 | 6 | 0.610 |
Why?
|
| Cost Savings | 5 | 2013 | 34 | 0.610 |
Why?
|
| Leg Dermatoses | 1 | 2019 | 1 | 0.600 |
Why?
|
| Skin Diseases, Genetic | 1 | 2019 | 4 | 0.600 |
Why?
|
| Patients | 5 | 2013 | 46 | 0.590 |
Why?
|
| Self Administration | 3 | 2010 | 382 | 0.580 |
Why?
|
| Bonding, Human-Pet | 1 | 2019 | 1 | 0.580 |
Why?
|
| Veterinarians | 1 | 2019 | 1 | 0.580 |
Why?
|
| Injections, Subcutaneous | 6 | 2019 | 36 | 0.580 |
Why?
|
| Animal Husbandry | 1 | 2019 | 8 | 0.580 |
Why?
|
| Perception | 5 | 2018 | 99 | 0.580 |
Why?
|
| Family Practice | 6 | 2015 | 49 | 0.580 |
Why?
|
| Finger Joint | 1 | 2019 | 14 | 0.580 |
Why?
|
| Skin Aging | 1 | 2019 | 9 | 0.580 |
Why?
|
| Fish Oils | 1 | 2019 | 38 | 0.580 |
Why?
|
| Electrocoagulation | 2 | 2016 | 11 | 0.580 |
Why?
|
| Morgellons Disease | 1 | 2018 | 3 | 0.580 |
Why?
|
| Chronic Disease | 12 | 2017 | 413 | 0.570 |
Why?
|
| Agriculture | 7 | 2013 | 94 | 0.570 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 29 | 0.570 |
Why?
|
| Fees and Charges | 2 | 2016 | 14 | 0.570 |
Why?
|
| Wound Infection | 1 | 2018 | 11 | 0.570 |
Why?
|
| Whole-Body Irradiation | 1 | 2019 | 58 | 0.570 |
Why?
|
| Aortitis | 1 | 2018 | 2 | 0.570 |
Why?
|
| Economics, Pharmaceutical | 4 | 2017 | 5 | 0.570 |
Why?
|
| Benchmarking | 4 | 2012 | 24 | 0.570 |
Why?
|
| Education, Medical, Graduate | 3 | 2015 | 130 | 0.570 |
Why?
|
| Patient-Centered Care | 2 | 2012 | 75 | 0.570 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 30 | 0.570 |
Why?
|
| Hepatitis B | 1 | 2018 | 17 | 0.570 |
Why?
|
| Cytokines | 2 | 2017 | 237 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 32 | 0.560 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 134 | 0.560 |
Why?
|
| Public Opinion | 2 | 2018 | 17 | 0.560 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 30 | 0.560 |
Why?
|
| Sick Leave | 1 | 2018 | 3 | 0.560 |
Why?
|
| Income | 2 | 2021 | 66 | 0.560 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 444 | 0.560 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2018 | 6 | 0.560 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 34 | 0.560 |
Why?
|
| Prescriptions | 3 | 2015 | 15 | 0.560 |
Why?
|
| Blood Donors | 1 | 2018 | 11 | 0.550 |
Why?
|
| Confidentiality | 1 | 2018 | 31 | 0.550 |
Why?
|
| Tinea | 2 | 2016 | 5 | 0.550 |
Why?
|
| Nails, Ingrown | 2 | 2015 | 5 | 0.550 |
Why?
|
| Porphyrins | 1 | 2018 | 29 | 0.550 |
Why?
|
| Health Services | 2 | 2017 | 40 | 0.550 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2018 | 15 | 0.550 |
Why?
|
| Injections | 5 | 2019 | 72 | 0.540 |
Why?
|
| Logistic Models | 10 | 2015 | 743 | 0.540 |
Why?
|
| Donor Selection | 1 | 2018 | 28 | 0.540 |
Why?
|
| Candidiasis, Chronic Mucocutaneous | 1 | 2017 | 1 | 0.540 |
Why?
|
| International Cooperation | 2 | 2020 | 31 | 0.540 |
Why?
|
| Caloric Restriction | 1 | 2019 | 92 | 0.540 |
Why?
|
| Efficiency | 4 | 2019 | 17 | 0.540 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 194 | 0.530 |
Why?
|
| Drug Resistance | 4 | 2018 | 42 | 0.530 |
Why?
|
| Academic Medical Centers | 5 | 2019 | 161 | 0.530 |
Why?
|
| Health Behavior | 3 | 2015 | 213 | 0.530 |
Why?
|
| Faculty, Medical | 2 | 2010 | 76 | 0.530 |
Why?
|
| Glioma | 1 | 2019 | 137 | 0.520 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 255 | 0.520 |
Why?
|
| Janus Kinases | 3 | 2016 | 4 | 0.520 |
Why?
|
| Photochemotherapy | 2 | 2017 | 14 | 0.520 |
Why?
|
| Alopecia Areata | 2 | 2015 | 16 | 0.520 |
Why?
|
| Medical Errors | 2 | 2010 | 34 | 0.520 |
Why?
|
| Drug Approval | 4 | 2019 | 13 | 0.520 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 164 | 0.510 |
Why?
|
| Residence Characteristics | 2 | 2017 | 178 | 0.510 |
Why?
|
| Nevus | 2 | 2015 | 17 | 0.510 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 16 | 0.510 |
Why?
|
| Staphylococcus aureus | 2 | 2019 | 55 | 0.510 |
Why?
|
| Parents | 3 | 2020 | 151 | 0.510 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 23 | 0.510 |
Why?
|
| Cohort Studies | 9 | 2018 | 1839 | 0.510 |
Why?
|
| Facial Neoplasms | 2 | 2008 | 9 | 0.510 |
Why?
|
| Sunlight | 6 | 2019 | 17 | 0.500 |
Why?
|
| Cellulitis | 1 | 2016 | 12 | 0.500 |
Why?
|
| Electrodes | 2 | 2016 | 20 | 0.500 |
Why?
|
| African Americans | 8 | 2017 | 1335 | 0.500 |
Why?
|
| Exanthema | 1 | 2016 | 19 | 0.490 |
Why?
|
| Outpatients | 6 | 2016 | 57 | 0.490 |
Why?
|
| Software | 2 | 2017 | 124 | 0.490 |
Why?
|
| Reproducibility of Results | 11 | 2020 | 756 | 0.490 |
Why?
|
| Abscess | 1 | 2016 | 28 | 0.490 |
Why?
|
| Online Systems | 1 | 2016 | 11 | 0.490 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 38 | 0.490 |
Why?
|
| Pyrazoles | 2 | 2017 | 77 | 0.490 |
Why?
|
| Zebrafish | 1 | 2016 | 23 | 0.490 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 93 | 0.490 |
Why?
|
| Biomimetic Materials | 1 | 2016 | 15 | 0.480 |
Why?
|
| Health Care Rationing | 2 | 2014 | 11 | 0.480 |
Why?
|
| Accidents, Traffic | 1 | 2018 | 204 | 0.480 |
Why?
|
| Electrosurgery | 3 | 2014 | 5 | 0.480 |
Why?
|
| Interpersonal Relations | 4 | 2017 | 58 | 0.480 |
Why?
|
| Skin Pigmentation | 5 | 2014 | 27 | 0.480 |
Why?
|
| Cryotherapy | 3 | 2012 | 12 | 0.470 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2006 | 3 | 0.470 |
Why?
|
| Medical Records | 4 | 2013 | 75 | 0.470 |
Why?
|
| European Continental Ancestry Group | 9 | 2017 | 1076 | 0.470 |
Why?
|
| Hydroquinones | 4 | 2014 | 7 | 0.470 |
Why?
|
| Occupational Diseases | 6 | 2014 | 48 | 0.460 |
Why?
|
| Mothers | 2 | 2013 | 74 | 0.460 |
Why?
|
| Naltrexone | 2 | 2006 | 23 | 0.460 |
Why?
|
| Empathy | 2 | 2013 | 17 | 0.460 |
Why?
|
| Body Surface Area | 3 | 2017 | 15 | 0.450 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2015 | 3 | 0.450 |
Why?
|
| Teratoma | 1 | 2015 | 9 | 0.450 |
Why?
|
| Diagnosis, Differential | 7 | 2018 | 500 | 0.450 |
Why?
|
| Etretinate | 2 | 2013 | 2 | 0.450 |
Why?
|
| Fee-for-Service Plans | 1 | 2015 | 14 | 0.450 |
Why?
|
| Costs and Cost Analysis | 5 | 2016 | 106 | 0.440 |
Why?
|
| Precancerous Conditions | 3 | 2011 | 23 | 0.440 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1081 | 0.440 |
Why?
|
| Needs Assessment | 3 | 2014 | 78 | 0.440 |
Why?
|
| Physical Examination | 3 | 2015 | 83 | 0.440 |
Why?
|
| Age Distribution | 6 | 2020 | 194 | 0.440 |
Why?
|
| Splints | 1 | 2014 | 13 | 0.440 |
Why?
|
| Arthritis | 1 | 2015 | 30 | 0.430 |
Why?
|
| Urocanic Acid | 1 | 2014 | 1 | 0.430 |
Why?
|
| Lipoxins | 1 | 2014 | 1 | 0.430 |
Why?
|
| Onycholysis | 1 | 2014 | 1 | 0.430 |
Why?
|
| Acrylates | 1 | 2014 | 2 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 363 | 0.430 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 14 | 0.430 |
Why?
|
| Electronic Mail | 2 | 2017 | 20 | 0.430 |
Why?
|
| Parathyroid Neoplasms | 1 | 2014 | 7 | 0.430 |
Why?
|
| Social Desirability | 1 | 2014 | 12 | 0.430 |
Why?
|
| Medically Underserved Area | 3 | 2013 | 17 | 0.430 |
Why?
|
| Single-Blind Method | 4 | 2020 | 192 | 0.430 |
Why?
|
| Surgical Wound Infection | 2 | 2014 | 98 | 0.420 |
Why?
|
| Electronic Health Records | 5 | 2018 | 179 | 0.420 |
Why?
|
| Quality Indicators, Health Care | 3 | 2015 | 62 | 0.420 |
Why?
|
| Antitubercular Agents | 1 | 2014 | 7 | 0.420 |
Why?
|
| Isoniazid | 1 | 2014 | 4 | 0.420 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2014 | 7 | 0.420 |
Why?
|
| Rural Health Services | 3 | 2009 | 23 | 0.420 |
Why?
|
| Self Medication | 2 | 2011 | 4 | 0.420 |
Why?
|
| Adenoma | 1 | 2014 | 35 | 0.420 |
Why?
|
| Excipients | 1 | 2014 | 2 | 0.420 |
Why?
|
| Erythromycin | 1 | 2014 | 8 | 0.420 |
Why?
|
| Home Nursing | 3 | 2010 | 9 | 0.420 |
Why?
|
| Case-Control Studies | 6 | 2020 | 854 | 0.420 |
Why?
|
| Anxiety | 7 | 2021 | 195 | 0.420 |
Why?
|
| Head and Neck Neoplasms | 3 | 2015 | 137 | 0.410 |
Why?
|
| Contraceptives, Oral | 2 | 2012 | 26 | 0.410 |
Why?
|
| Gynecomastia | 1 | 2014 | 2 | 0.410 |
Why?
|
| Webcasts as Topic | 2 | 2012 | 3 | 0.410 |
Why?
|
| Scurvy | 1 | 2013 | 3 | 0.410 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 42 | 0.410 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2019 | 9 | 0.400 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2014 | 149 | 0.400 |
Why?
|
| Flutamide | 1 | 2013 | 4 | 0.400 |
Why?
|
| Hydroxy Acids | 1 | 2013 | 2 | 0.400 |
Why?
|
| Clinical Competence | 5 | 2015 | 329 | 0.400 |
Why?
|
| Socioeconomic Factors | 6 | 2018 | 388 | 0.400 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 40 | 0.400 |
Why?
|
| Folic Acid Deficiency | 1 | 2013 | 2 | 0.400 |
Why?
|
| Folic Acid Antagonists | 1 | 2013 | 3 | 0.400 |
Why?
|
| Herpes Labialis | 1 | 2013 | 1 | 0.400 |
Why?
|
| Drug Eruptions | 1 | 2013 | 9 | 0.390 |
Why?
|
| Transportation | 1 | 2013 | 10 | 0.390 |
Why?
|
| Physician Assistants | 3 | 2010 | 39 | 0.390 |
Why?
|
| Breast | 1 | 2014 | 63 | 0.390 |
Why?
|
| Folic Acid | 1 | 2013 | 11 | 0.390 |
Why?
|
| Drug Tolerance | 1 | 2013 | 40 | 0.390 |
Why?
|
| Health Surveys | 8 | 2019 | 175 | 0.390 |
Why?
|
| Consensus | 4 | 2020 | 87 | 0.390 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 87 | 0.390 |
Why?
|
| Dermatomycoses | 3 | 2009 | 7 | 0.390 |
Why?
|
| Disease Progression | 4 | 2018 | 591 | 0.390 |
Why?
|
| HIV Infections | 1 | 2018 | 450 | 0.380 |
Why?
|
| Mouth | 1 | 2013 | 23 | 0.380 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2012 | 1 | 0.380 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 47 | 0.380 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2012 | 4 | 0.380 |
Why?
|
| Decision Making | 2 | 2019 | 190 | 0.380 |
Why?
|
| Health Services Research | 3 | 2010 | 81 | 0.380 |
Why?
|
| Patch Tests | 4 | 2010 | 7 | 0.370 |
Why?
|
| Progestins | 1 | 2012 | 27 | 0.370 |
Why?
|
| Telephone | 4 | 2018 | 61 | 0.370 |
Why?
|
| Employment | 2 | 2018 | 45 | 0.370 |
Why?
|
| Hydrocortisone | 2 | 2011 | 64 | 0.360 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 132 | 0.360 |
Why?
|
| Antimetabolites | 1 | 2012 | 11 | 0.360 |
Why?
|
| Cosmetics | 3 | 2010 | 11 | 0.360 |
Why?
|
| Arthrodermataceae | 2 | 2009 | 3 | 0.360 |
Why?
|
| Organ Transplantation | 1 | 2012 | 67 | 0.360 |
Why?
|
| Health Status | 3 | 2011 | 356 | 0.360 |
Why?
|
| Choice Behavior | 3 | 2019 | 84 | 0.350 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2014 | 40 | 0.350 |
Why?
|
| Data Collection | 6 | 2014 | 171 | 0.350 |
Why?
|
| Practice Management, Medical | 2 | 2013 | 7 | 0.350 |
Why?
|
| Fluocinolone Acetonide | 2 | 2012 | 5 | 0.350 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 232 | 0.350 |
Why?
|
| Self Efficacy | 3 | 2017 | 74 | 0.350 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 9 | 0.350 |
Why?
|
| Self-Examination | 1 | 2011 | 1 | 0.340 |
Why?
|
| Propionibacterium acnes | 4 | 2014 | 4 | 0.340 |
Why?
|
| Regression Analysis | 6 | 2017 | 273 | 0.340 |
Why?
|
| Diet | 1 | 2013 | 383 | 0.340 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2011 | 1 | 0.340 |
Why?
|
| Information Dissemination | 2 | 2009 | 52 | 0.340 |
Why?
|
| Foundations | 2 | 2008 | 8 | 0.340 |
Why?
|
| Zinc | 2 | 2019 | 29 | 0.340 |
Why?
|
| Photosensitizing Agents | 3 | 2010 | 16 | 0.340 |
Why?
|
| Estrogens | 1 | 2012 | 194 | 0.340 |
Why?
|
| Odds Ratio | 6 | 2017 | 455 | 0.340 |
Why?
|
| Appointments and Schedules | 2 | 2020 | 21 | 0.340 |
Why?
|
| Molluscum Contagiosum | 2 | 2015 | 3 | 0.340 |
Why?
|
| Computer Peripherals | 1 | 2010 | 1 | 0.330 |
Why?
|
| Friction | 1 | 2010 | 5 | 0.330 |
Why?
|
| Educational Status | 4 | 2020 | 168 | 0.330 |
Why?
|
| Clotrimazole | 3 | 2007 | 4 | 0.330 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 73 | 0.330 |
Why?
|
| Eyeglasses | 1 | 2010 | 2 | 0.330 |
Why?
|
| Linear Models | 4 | 2019 | 426 | 0.330 |
Why?
|
| Pregnancy | 9 | 2019 | 960 | 0.330 |
Why?
|
| Life Style | 1 | 2013 | 394 | 0.320 |
Why?
|
| Risk-Taking | 2 | 2009 | 96 | 0.320 |
Why?
|
| Chromium | 1 | 2010 | 1 | 0.320 |
Why?
|
| Nickel | 1 | 2010 | 2 | 0.320 |
Why?
|
| Prospective Studies | 7 | 2018 | 2315 | 0.320 |
Why?
|
| Frozen Sections | 1 | 2010 | 19 | 0.320 |
Why?
|
| Health Services Misuse | 1 | 2010 | 7 | 0.320 |
Why?
|
| Pharmaceutical Services | 1 | 2010 | 7 | 0.320 |
Why?
|
| Desonide | 1 | 2010 | 1 | 0.320 |
Why?
|
| Algorithms | 6 | 2015 | 536 | 0.320 |
Why?
|
| Vitamin E | 1 | 2010 | 19 | 0.320 |
Why?
|
| Publications | 1 | 2010 | 9 | 0.310 |
Why?
|
| Ear Cartilage | 1 | 2010 | 12 | 0.310 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2014 | 48 | 0.310 |
Why?
|
| Medically Uninsured | 1 | 2010 | 35 | 0.310 |
Why?
|
| Textiles | 1 | 2009 | 1 | 0.310 |
Why?
|
| Clothing | 1 | 2009 | 5 | 0.310 |
Why?
|
| Patient Participation | 2 | 2014 | 90 | 0.310 |
Why?
|
| Cartilage Diseases | 1 | 2010 | 18 | 0.310 |
Why?
|
| Social Marketing | 1 | 2010 | 14 | 0.310 |
Why?
|
| Financing, Personal | 2 | 2014 | 6 | 0.310 |
Why?
|
| Communicable Diseases | 1 | 2009 | 17 | 0.300 |
Why?
|
| Health Care Reform | 1 | 2010 | 45 | 0.300 |
Why?
|
| Marketing | 1 | 2010 | 39 | 0.300 |
Why?
|
| Cost Sharing | 2 | 2006 | 9 | 0.300 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 116 | 0.300 |
Why?
|
| Education, Medical | 1 | 2010 | 69 | 0.300 |
Why?
|
| General Surgery | 3 | 2014 | 84 | 0.300 |
Why?
|
| Mandatory Reporting | 3 | 2006 | 7 | 0.300 |
Why?
|
| Dermatitis, Perioral | 1 | 2009 | 1 | 0.300 |
Why?
|
| Triage | 2 | 2010 | 68 | 0.300 |
Why?
|
| Burnout, Professional | 2 | 2021 | 54 | 0.290 |
Why?
|
| Risk Management | 2 | 2006 | 22 | 0.290 |
Why?
|
| Insurance Carriers | 1 | 2009 | 18 | 0.290 |
Why?
|
| Occupational Exposure | 5 | 2009 | 159 | 0.290 |
Why?
|
| Elastic Tissue | 1 | 2009 | 2 | 0.290 |
Why?
|
| Radio Waves | 1 | 2009 | 6 | 0.290 |
Why?
|
| Neoplasms | 3 | 2017 | 763 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1437 | 0.290 |
Why?
|
| Physicians' Offices | 3 | 2005 | 9 | 0.290 |
Why?
|
| Narcotic Antagonists | 2 | 2006 | 47 | 0.290 |
Why?
|
| Fibromyalgia | 1 | 2009 | 12 | 0.290 |
Why?
|
| Mass Screening | 3 | 2017 | 256 | 0.290 |
Why?
|
| Sirolimus | 1 | 2009 | 34 | 0.290 |
Why?
|
| Pamphlets | 2 | 2007 | 5 | 0.280 |
Why?
|
| Language | 3 | 2007 | 35 | 0.280 |
Why?
|
| Social Support | 3 | 2017 | 181 | 0.280 |
Why?
|
| Placebos | 3 | 2020 | 68 | 0.280 |
Why?
|
| Internal Medicine | 4 | 2015 | 53 | 0.280 |
Why?
|
| Guideline Adherence | 3 | 2015 | 109 | 0.280 |
Why?
|
| Fluocortolone | 1 | 2008 | 1 | 0.280 |
Why?
|
| Interleukin-12 | 2 | 2008 | 29 | 0.280 |
Why?
|
| Safety | 5 | 2011 | 65 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 110 | 0.270 |
Why?
|
| Selection Bias | 1 | 2008 | 13 | 0.270 |
Why?
|
| Hand | 2 | 2019 | 81 | 0.270 |
Why?
|
| Colitis, Ulcerative | 2 | 2018 | 24 | 0.270 |
Why?
|
| Crohn Disease | 2 | 2019 | 31 | 0.270 |
Why?
|
| Histamine Antagonists | 3 | 2018 | 5 | 0.270 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 180 | 0.270 |
Why?
|
| Social Problems | 1 | 2007 | 2 | 0.270 |
Why?
|
| Interviews as Topic | 6 | 2017 | 195 | 0.270 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2007 | 3 | 0.260 |
Why?
|
| Internationality | 1 | 2007 | 22 | 0.260 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2017 | 33 | 0.260 |
Why?
|
| Asian Continental Ancestry Group | 3 | 2014 | 101 | 0.260 |
Why?
|
| Episode of Care | 2 | 2004 | 5 | 0.260 |
Why?
|
| Pregnancy Outcome | 2 | 2018 | 86 | 0.260 |
Why?
|
| Interleukins | 2 | 2017 | 17 | 0.250 |
Why?
|
| Absenteeism | 3 | 2018 | 10 | 0.250 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2007 | 5 | 0.250 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 140 | 0.250 |
Why?
|
| Career Choice | 1 | 2007 | 43 | 0.250 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 51 | 0.250 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2017 | 28 | 0.250 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 51 | 0.250 |
Why?
|
| Forms and Records Control | 1 | 2006 | 8 | 0.250 |
Why?
|
| Electronics | 1 | 2006 | 15 | 0.250 |
Why?
|
| Personality | 3 | 2014 | 15 | 0.250 |
Why?
|
| beta-Endorphin | 1 | 2006 | 1 | 0.240 |
Why?
|
| Tachyphylaxis | 1 | 2006 | 1 | 0.240 |
Why?
|
| Multiple Sclerosis | 1 | 2007 | 62 | 0.240 |
Why?
|
| Women | 1 | 2006 | 12 | 0.240 |
Why?
|
| Seasons | 4 | 2017 | 74 | 0.230 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2007 | 191 | 0.230 |
Why?
|
| Evaluation Studies as Topic | 2 | 2016 | 39 | 0.230 |
Why?
|
| Carcinoma | 1 | 2006 | 92 | 0.230 |
Why?
|
| Health Services for the Aged | 2 | 2007 | 24 | 0.230 |
Why?
|
| Surgicenters | 2 | 2004 | 2 | 0.230 |
Why?
|
| Complementary Therapies | 2 | 2017 | 44 | 0.230 |
Why?
|
| Anti-Allergic Agents | 2 | 2017 | 6 | 0.230 |
Why?
|
| Europe | 3 | 2015 | 82 | 0.230 |
Why?
|
| Insurance Benefits | 1 | 2005 | 4 | 0.230 |
Why?
|
| Acne Keloid | 1 | 2005 | 2 | 0.230 |
Why?
|
| Social Behavior | 1 | 2006 | 69 | 0.230 |
Why?
|
| Insurance Claim Review | 2 | 2019 | 26 | 0.230 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 556 | 0.220 |
Why?
|
| Withholding Treatment | 2 | 2018 | 13 | 0.220 |
Why?
|
| Narcotics | 1 | 2005 | 32 | 0.220 |
Why?
|
| Heliotherapy | 1 | 2005 | 3 | 0.220 |
Why?
|
| Fear | 2 | 2019 | 42 | 0.220 |
Why?
|
| Hospital Charges | 1 | 2005 | 15 | 0.220 |
Why?
|
| Sex Distribution | 3 | 2017 | 174 | 0.220 |
Why?
|
| Tinea Pedis | 2 | 2015 | 4 | 0.220 |
Why?
|
| Relaxation | 2 | 2019 | 9 | 0.220 |
Why?
|
| Rheumatology | 3 | 2020 | 10 | 0.220 |
Why?
|
| Dietary Supplements | 2 | 2019 | 188 | 0.210 |
Why?
|
| Age of Onset | 3 | 2020 | 91 | 0.210 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2018 | 13 | 0.210 |
Why?
|
| Automobiles | 2 | 2014 | 19 | 0.210 |
Why?
|
| Bioterrorism | 1 | 2003 | 7 | 0.200 |
Why?
|
| Meat-Packing Industry | 2 | 2014 | 3 | 0.200 |
Why?
|
| Occupational Health | 3 | 2015 | 42 | 0.200 |
Why?
|
| Early Diagnosis | 2 | 2017 | 57 | 0.200 |
Why?
|
| Disclosure | 1 | 2003 | 31 | 0.200 |
Why?
|
| Itraconazole | 1 | 2003 | 5 | 0.200 |
Why?
|
| Organometallic Compounds | 1 | 2003 | 18 | 0.200 |
Why?
|
| Iran | 2 | 2013 | 5 | 0.200 |
Why?
|
| Referral and Consultation | 3 | 2011 | 137 | 0.200 |
Why?
|
| Prognosis | 6 | 2019 | 1529 | 0.200 |
Why?
|
| Pyridines | 1 | 2003 | 79 | 0.190 |
Why?
|
| Program Development | 2 | 2018 | 93 | 0.190 |
Why?
|
| Current Procedural Terminology | 1 | 2003 | 3 | 0.190 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 3 | 0.190 |
Why?
|
| Tonsillitis | 1 | 2003 | 7 | 0.190 |
Why?
|
| Pregnancy Complications | 2 | 2009 | 109 | 0.190 |
Why?
|
| Directive Counseling | 1 | 2002 | 19 | 0.190 |
Why?
|
| Analysis of Variance | 4 | 2020 | 471 | 0.190 |
Why?
|
| Demography | 2 | 2020 | 101 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 140 | 0.190 |
Why?
|
| Aminoquinolines | 2 | 2015 | 18 | 0.190 |
Why?
|
| Emigrants and Immigrants | 3 | 2014 | 198 | 0.190 |
Why?
|
| Nausea | 1 | 2002 | 50 | 0.190 |
Why?
|
| Qualitative Research | 3 | 2018 | 180 | 0.190 |
Why?
|
| Diabetes Mellitus | 3 | 2015 | 390 | 0.180 |
Why?
|
| Drugs, Investigational | 2 | 2020 | 9 | 0.180 |
Why?
|
| Food-Processing Industry | 3 | 2013 | 21 | 0.180 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 78 | 0.180 |
Why?
|
| Hypnotics and Sedatives | 1 | 2002 | 31 | 0.180 |
Why?
|
| Equipment Design | 3 | 2014 | 178 | 0.180 |
Why?
|
| Drug Administration Routes | 3 | 2012 | 13 | 0.180 |
Why?
|
| Mice, Knockout | 2 | 2017 | 454 | 0.180 |
Why?
|
| Solutions | 2 | 2016 | 40 | 0.170 |
Why?
|
| Dosage Forms | 2 | 2012 | 4 | 0.170 |
Why?
|
| Psychometrics | 4 | 2015 | 137 | 0.170 |
Why?
|
| Liver | 2 | 2016 | 492 | 0.170 |
Why?
|
| Mice | 4 | 2017 | 2571 | 0.170 |
Why?
|
| Diterpenes | 1 | 2021 | 22 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2002 | 115 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2020 | 62 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2020 | 74 | 0.160 |
Why?
|
| Models, Econometric | 2 | 2017 | 8 | 0.160 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 5 | 0.160 |
Why?
|
| Pain Measurement | 3 | 2018 | 339 | 0.160 |
Why?
|
| Societies, Medical | 3 | 2019 | 153 | 0.160 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 75 | 0.160 |
Why?
|
| Postoperative Care | 2 | 2018 | 79 | 0.160 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 10 | 0.160 |
Why?
|
| Employee Retirement Income Security Act | 1 | 2020 | 5 | 0.160 |
Why?
|
| Face | 2 | 2017 | 29 | 0.160 |
Why?
|
| Steroids | 1 | 2020 | 35 | 0.160 |
Why?
|
| Pharmacy | 1 | 2020 | 2 | 0.160 |
Why?
|
| Tuberculin | 1 | 2020 | 1 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2013 | 59 | 0.160 |
Why?
|
| Aminolevulinic Acid | 1 | 2020 | 8 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2020 | 12 | 0.160 |
Why?
|
| Japan | 1 | 2020 | 19 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 14 | 0.160 |
Why?
|
| Mycobacterium | 1 | 2020 | 3 | 0.160 |
Why?
|
| Bacterial Vaccines | 1 | 2020 | 8 | 0.160 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 11 | 0.160 |
Why?
|
| BCG Vaccine | 1 | 2020 | 8 | 0.160 |
Why?
|
| Informed Consent | 1 | 2020 | 44 | 0.160 |
Why?
|
| Drug Synergism | 1 | 2020 | 66 | 0.160 |
Why?
|
| China | 1 | 2020 | 56 | 0.160 |
Why?
|
| Blood Cell Count | 1 | 2020 | 28 | 0.160 |
Why?
|
| Asthma | 2 | 2015 | 262 | 0.150 |
Why?
|
| Sampling Studies | 3 | 2009 | 42 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2020 | 68 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 101 | 0.150 |
Why?
|
| Metabolome | 1 | 2020 | 37 | 0.150 |
Why?
|
| Neurodermatitis | 1 | 2019 | 3 | 0.150 |
Why?
|
| Congresses as Topic | 2 | 2012 | 42 | 0.150 |
Why?
|
| Students, Medical | 1 | 2021 | 126 | 0.150 |
Why?
|
| Women's Health | 1 | 2021 | 230 | 0.150 |
Why?
|
| Ficusin | 3 | 2010 | 5 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2011 | 77 | 0.150 |
Why?
|
| Thorax | 1 | 2019 | 32 | 0.150 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 128 | 0.150 |
Why?
|
| Authorship | 1 | 2019 | 9 | 0.150 |
Why?
|
| Patient Care Team | 2 | 2010 | 123 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 16 | 0.150 |
Why?
|
| Random Allocation | 1 | 2020 | 247 | 0.150 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.150 |
Why?
|
| Arm | 1 | 2019 | 42 | 0.150 |
Why?
|
| Diet, Gluten-Free | 1 | 2019 | 3 | 0.150 |
Why?
|
| Selenium | 1 | 2019 | 3 | 0.150 |
Why?
|
| Malassezia | 1 | 2019 | 1 | 0.150 |
Why?
|
| Work Schedule Tolerance | 1 | 2019 | 7 | 0.150 |
Why?
|
| Herpes Zoster | 1 | 2019 | 12 | 0.150 |
Why?
|
| Periodontitis | 1 | 2019 | 10 | 0.150 |
Why?
|
| Croton | 1 | 2018 | 2 | 0.150 |
Why?
|
| Hyperhidrosis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Candida albicans | 1 | 2019 | 13 | 0.150 |
Why?
|
| Streptococcus pyogenes | 1 | 2019 | 16 | 0.150 |
Why?
|
| Probiotics | 1 | 2019 | 9 | 0.150 |
Why?
|
| Paternal Exposure | 1 | 2018 | 1 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2010 | 120 | 0.140 |
Why?
|
| Databases as Topic | 1 | 2018 | 20 | 0.140 |
Why?
|
| Glossitis, Benign Migratory | 1 | 2018 | 2 | 0.140 |
Why?
|
| Risperidone | 1 | 2018 | 4 | 0.140 |
Why?
|
| Maternal Exposure | 1 | 2018 | 11 | 0.140 |
Why?
|
| Trifluoperazine | 1 | 2018 | 4 | 0.140 |
Why?
|
| Fatigue | 2 | 2009 | 80 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 34 | 0.140 |
Why?
|
| Virus Activation | 1 | 2018 | 8 | 0.140 |
Why?
|
| Immune Tolerance | 1 | 2019 | 66 | 0.140 |
Why?
|
| Red Cross | 1 | 2018 | 2 | 0.140 |
Why?
|
| Primates | 1 | 2019 | 128 | 0.140 |
Why?
|
| Skin Absorption | 3 | 2009 | 5 | 0.140 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 24 | 0.140 |
Why?
|
| World Health Organization | 1 | 2018 | 17 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2014 | 818 | 0.140 |
Why?
|
| Antiparasitic Agents | 1 | 2018 | 6 | 0.140 |
Why?
|
| Fees, Pharmaceutical | 1 | 2018 | 2 | 0.140 |
Why?
|
| Models, Organizational | 1 | 2018 | 18 | 0.140 |
Why?
|
| Expert Testimony | 1 | 2018 | 11 | 0.140 |
Why?
|
| Rhinophyma | 1 | 2017 | 2 | 0.140 |
Why?
|
| Adamantane | 1 | 2017 | 3 | 0.140 |
Why?
|
| Lidocaine | 1 | 2018 | 19 | 0.140 |
Why?
|
| Self-Help Groups | 1 | 2017 | 11 | 0.130 |
Why?
|
| Internal-External Control | 1 | 2017 | 14 | 0.130 |
Why?
|
| Niacinamide | 1 | 2017 | 8 | 0.130 |
Why?
|
| Epinephrine | 1 | 2018 | 44 | 0.130 |
Why?
|
| Keratinocytes | 2 | 2015 | 30 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 33 | 0.130 |
Why?
|
| Social Perception | 1 | 2017 | 22 | 0.130 |
Why?
|
| Information Services | 2 | 2009 | 11 | 0.130 |
Why?
|
| Genes, Essential | 1 | 2017 | 4 | 0.130 |
Why?
|
| Longitudinal Studies | 7 | 2009 | 759 | 0.130 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2017 | 23 | 0.130 |
Why?
|
| Tobacco | 2 | 2008 | 43 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 37 | 0.130 |
Why?
|
| Pituitary-Adrenal System | 1 | 2017 | 23 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 39 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 50 | 0.130 |
Why?
|
| Videodisc Recording | 1 | 2017 | 3 | 0.130 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 85 | 0.130 |
Why?
|
| Markov Chains | 1 | 2017 | 31 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 595 | 0.130 |
Why?
|
| Coronary Disease | 1 | 2018 | 226 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2009 | 76 | 0.130 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 36 | 0.130 |
Why?
|
| Patient Advocacy | 2 | 2008 | 11 | 0.130 |
Why?
|
| Lentigo | 2 | 2008 | 4 | 0.130 |
Why?
|
| African Continental Ancestry Group | 4 | 2011 | 338 | 0.120 |
Why?
|
| Journalism, Medical | 1 | 2016 | 1 | 0.120 |
Why?
|
| Workers' Compensation | 2 | 2006 | 3 | 0.120 |
Why?
|
| Quality Control | 1 | 2016 | 43 | 0.120 |
Why?
|
| Cattle | 1 | 2016 | 116 | 0.120 |
Why?
|
| Th2 Cells | 1 | 2015 | 9 | 0.120 |
Why?
|
| Minoxidil | 1 | 2015 | 6 | 0.110 |
Why?
|
| Interleukin-4 | 1 | 2015 | 22 | 0.110 |
Why?
|
| Probability | 4 | 2009 | 155 | 0.110 |
Why?
|
| Health Education | 2 | 2007 | 149 | 0.110 |
Why?
|
| Interleukin-13 | 1 | 2015 | 29 | 0.110 |
Why?
|
| Moving and Lifting Patients | 1 | 2015 | 1 | 0.110 |
Why?
|
| Electronic Prescribing | 1 | 2015 | 2 | 0.110 |
Why?
|
| Emergency Medicine | 1 | 2016 | 110 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 62 | 0.110 |
Why?
|
| Botulinum Toxins | 1 | 2015 | 30 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 56 | 0.110 |
Why?
|
| Florida | 2 | 2005 | 41 | 0.110 |
Why?
|
| Canada | 2 | 2013 | 63 | 0.110 |
Why?
|
| Teaching | 1 | 2015 | 60 | 0.110 |
Why?
|
| Ulcer | 1 | 2014 | 2 | 0.110 |
Why?
|
| Medical Informatics | 2 | 2007 | 26 | 0.110 |
Why?
|
| Musculoskeletal Diseases | 1 | 2015 | 33 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 92 | 0.110 |
Why?
|
| Occlusive Dressings | 1 | 2014 | 10 | 0.110 |
Why?
|
| Suspensions | 1 | 2014 | 2 | 0.110 |
Why?
|
| Cyanoacrylates | 1 | 2014 | 2 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2015 | 48 | 0.110 |
Why?
|
| Toes | 1 | 2014 | 13 | 0.110 |
Why?
|
| Oceanic Ancestry Group | 1 | 2014 | 4 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 35 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 11 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 12 | 0.110 |
Why?
|
| Education, Medical, Continuing | 3 | 2014 | 49 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2014 | 13 | 0.110 |
Why?
|
| Minocycline | 1 | 2014 | 11 | 0.110 |
Why?
|
| Hypericum | 1 | 2014 | 2 | 0.110 |
Why?
|
| Herb-Drug Interactions | 1 | 2014 | 2 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 31 | 0.110 |
Why?
|
| Resource Allocation | 1 | 2014 | 8 | 0.110 |
Why?
|
| Leukemia, Lymphoid | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pancytopenia | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 18 | 0.110 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2014 | 17 | 0.110 |
Why?
|
| Single Person | 1 | 2014 | 3 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 18 | 0.100 |
Why?
|
| Phytotherapy | 1 | 2014 | 36 | 0.100 |
Why?
|
| Unemployment | 1 | 2014 | 4 | 0.100 |
Why?
|
| Medical Staff | 1 | 2014 | 1 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2014 | 64 | 0.100 |
Why?
|
| Health Personnel | 1 | 2015 | 112 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2014 | 86 | 0.100 |
Why?
|
| Sarcomeres | 1 | 2014 | 5 | 0.100 |
Why?
|
| NADPH Dehydrogenase | 1 | 2014 | 3 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2014 | 55 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2014 | 12 | 0.100 |
Why?
|
| Actigraphy | 1 | 2014 | 15 | 0.100 |
Why?
|
| Remission Induction | 2 | 2005 | 92 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 32 | 0.100 |
Why?
|
| Mental Recall | 1 | 2014 | 48 | 0.100 |
Why?
|
| Polysomnography | 1 | 2014 | 39 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 37 | 0.100 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 4 | 0.100 |
Why?
|
| Terminology as Topic | 2 | 2005 | 68 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 81 | 0.100 |
Why?
|
| Muscle Development | 1 | 2014 | 52 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2014 | 51 | 0.100 |
Why?
|
| Gasoline | 1 | 2013 | 2 | 0.100 |
Why?
|
| Lighting | 1 | 2013 | 5 | 0.100 |
Why?
|
| Feedback | 1 | 2013 | 41 | 0.100 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2013 | 4 | 0.100 |
Why?
|
| Biotechnology | 1 | 2013 | 8 | 0.100 |
Why?
|
| Valine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Acyclovir | 1 | 2013 | 14 | 0.100 |
Why?
|
| Medical Waste Disposal | 1 | 2013 | 2 | 0.100 |
Why?
|
| Herpes Simplex | 1 | 2013 | 14 | 0.100 |
Why?
|
| Needles | 1 | 2013 | 28 | 0.100 |
Why?
|
| Keloid | 1 | 2013 | 8 | 0.100 |
Why?
|
| Housing | 1 | 2013 | 35 | 0.100 |
Why?
|
| Vitamins | 1 | 2013 | 70 | 0.100 |
Why?
|
| Ketoconazole | 1 | 2013 | 5 | 0.100 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2013 | 4 | 0.100 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 44 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 22 | 0.100 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2012 | 9 | 0.090 |
Why?
|
| Otolaryngology | 1 | 2013 | 15 | 0.090 |
Why?
|
| Sarcoma, Kaposi | 1 | 2012 | 9 | 0.090 |
Why?
|
| Myocardium | 1 | 2014 | 184 | 0.090 |
Why?
|
| Culture | 1 | 2012 | 34 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2013 | 66 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 16 | 0.090 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2012 | 13 | 0.090 |
Why?
|
| Fibroma | 1 | 2012 | 11 | 0.090 |
Why?
|
| Fractures, Bone | 1 | 2014 | 142 | 0.090 |
Why?
|
| Mexico | 3 | 2007 | 47 | 0.090 |
Why?
|
| Immunosuppression | 1 | 2012 | 118 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2012 | 14 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 772 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 37 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2012 | 9 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2010 | 141 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 73 | 0.090 |
Why?
|
| Medicine, Traditional | 2 | 2009 | 10 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 22 | 0.090 |
Why?
|
| Puberty, Precocious | 1 | 2011 | 2 | 0.090 |
Why?
|
| Specialty Boards | 1 | 2011 | 10 | 0.090 |
Why?
|
| Horses | 1 | 2011 | 18 | 0.090 |
Why?
|
| Milk | 1 | 2011 | 13 | 0.090 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2011 | 7 | 0.090 |
Why?
|
| Disinfection | 1 | 2011 | 6 | 0.090 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 88 | 0.090 |
Why?
|
| Bandages | 1 | 2011 | 34 | 0.090 |
Why?
|
| Recurrence | 2 | 2003 | 286 | 0.090 |
Why?
|
| Stress, Psychological | 3 | 2009 | 229 | 0.090 |
Why?
|
| Histamine H1 Antagonists | 2 | 2008 | 8 | 0.080 |
Why?
|
| Plasticizers | 1 | 2010 | 1 | 0.080 |
Why?
|
| Computer Terminals | 1 | 2010 | 1 | 0.080 |
Why?
|
| Latex Hypersensitivity | 1 | 2010 | 1 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 442 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 544 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 14 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 942 | 0.080 |
Why?
|
| Nurse Practitioners | 1 | 2010 | 12 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2011 | 59 | 0.080 |
Why?
|
| Pathology, Clinical | 1 | 2010 | 11 | 0.080 |
Why?
|
| Total Quality Management | 1 | 2010 | 17 | 0.080 |
Why?
|
| Waiting Lists | 2 | 2007 | 35 | 0.080 |
Why?
|
| Pennsylvania | 2 | 2018 | 80 | 0.080 |
Why?
|
| Emigration and Immigration | 2 | 2013 | 19 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2013 | 211 | 0.080 |
Why?
|
| Time | 1 | 2010 | 27 | 0.080 |
Why?
|
| Durable Medical Equipment | 1 | 2010 | 2 | 0.080 |
Why?
|
| Ethics, Business | 1 | 2010 | 2 | 0.080 |
Why?
|
| Conditioning, Classical | 1 | 2010 | 30 | 0.080 |
Why?
|
| Hygiene | 2 | 2007 | 9 | 0.080 |
Why?
|
| Hydroxides | 1 | 2009 | 1 | 0.080 |
Why?
|
| Mycology | 1 | 2009 | 1 | 0.080 |
Why?
|
| North Dakota | 1 | 2009 | 1 | 0.080 |
Why?
|
| Potassium Compounds | 1 | 2009 | 2 | 0.080 |
Why?
|
| Blood-Borne Pathogens | 1 | 2009 | 5 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 15 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2009 | 14 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2009 | 31 | 0.080 |
Why?
|
| Sample Size | 2 | 2013 | 38 | 0.080 |
Why?
|
| Observer Variation | 2 | 2020 | 96 | 0.080 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Boston | 1 | 2009 | 16 | 0.070 |
Why?
|
| Deductibles and Coinsurance | 1 | 2009 | 3 | 0.070 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 56 | 0.070 |
Why?
|
| Beauty | 1 | 2008 | 5 | 0.070 |
Why?
|
| Rheumatic Diseases | 1 | 2009 | 8 | 0.070 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2008 | 2 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2012 | 727 | 0.070 |
Why?
|
| Forecasting | 3 | 2003 | 144 | 0.070 |
Why?
|
| Arthralgia | 1 | 2009 | 29 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2008 | 27 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 54 | 0.070 |
Why?
|
| Health Maintenance Organizations | 2 | 2006 | 16 | 0.070 |
Why?
|
| Microspheres | 1 | 2008 | 45 | 0.070 |
Why?
|
| Electronics, Medical | 1 | 2008 | 1 | 0.070 |
Why?
|
| Dermatitis, Irritant | 1 | 2008 | 1 | 0.070 |
Why?
|
| Sodium Hypochlorite | 1 | 2008 | 2 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 24 | 0.070 |
Why?
|
| Acute Disease | 2 | 2006 | 253 | 0.070 |
Why?
|
| Detergents | 1 | 2008 | 17 | 0.070 |
Why?
|
| Eye Protective Devices | 1 | 2008 | 4 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2008 | 23 | 0.070 |
Why?
|
| Tuberculin Test | 1 | 2007 | 2 | 0.070 |
Why?
|
| Lichen Planus, Oral | 1 | 2008 | 11 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 106 | 0.070 |
Why?
|
| Parent-Child Relations | 2 | 2010 | 45 | 0.070 |
Why?
|
| Toxoplasmosis, Animal | 1 | 2007 | 1 | 0.070 |
Why?
|
| Leishmaniasis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2008 | 103 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 99 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 47 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Artifacts | 1 | 2007 | 45 | 0.070 |
Why?
|
| Drug Evaluation | 2 | 2004 | 15 | 0.070 |
Why?
|
| Prejudice | 1 | 2007 | 45 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2007 | 21 | 0.070 |
Why?
|
| Communication Barriers | 1 | 2007 | 18 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2007 | 45 | 0.060 |
Why?
|
| Ohio | 1 | 2007 | 63 | 0.060 |
Why?
|
| Larva Migrans | 1 | 2007 | 1 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2007 | 15 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 19 | 0.060 |
Why?
|
| Microcomputers | 1 | 2006 | 6 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 408 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 880 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 13 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2007 | 83 | 0.060 |
Why?
|
| Focus Groups | 2 | 2006 | 123 | 0.060 |
Why?
|
| Vitamin A | 1 | 2006 | 21 | 0.060 |
Why?
|
| Lipectomy | 2 | 2003 | 8 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2006 | 90 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2006 | 2 | 0.060 |
Why?
|
| Eye Abnormalities | 1 | 2006 | 2 | 0.060 |
Why?
|
| Pterygium | 1 | 2006 | 2 | 0.060 |
Why?
|
| Social Adjustment | 1 | 2006 | 11 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2008 | 373 | 0.060 |
Why?
|
| Skin Irritancy Tests | 1 | 2005 | 1 | 0.060 |
Why?
|
| Irritants | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nicotine | 1 | 2008 | 164 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2017 | 59 | 0.060 |
Why?
|
| Body Size | 1 | 2005 | 35 | 0.060 |
Why?
|
| Pleistophora | 1 | 2005 | 1 | 0.060 |
Why?
|
| Credentialing | 1 | 2005 | 7 | 0.060 |
Why?
|
| Dermatomyositis | 1 | 2005 | 18 | 0.060 |
Why?
|
| Drug Storage | 1 | 2005 | 5 | 0.060 |
Why?
|
| Candidiasis, Cutaneous | 2 | 2002 | 2 | 0.060 |
Why?
|
| Poultry Products | 1 | 2005 | 8 | 0.060 |
Why?
|
| Child Health Services | 1 | 2005 | 24 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2005 | 34 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2006 | 113 | 0.060 |
Why?
|
| Family Health | 1 | 2005 | 73 | 0.060 |
Why?
|
| Anesthesia | 1 | 2005 | 63 | 0.050 |
Why?
|
| Inpatients | 1 | 2005 | 83 | 0.050 |
Why?
|
| Chemexfoliation | 1 | 2004 | 2 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2004 | 2 | 0.050 |
Why?
|
| Texas | 1 | 2004 | 41 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2004 | 12 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 91 | 0.050 |
Why?
|
| Morbidity | 1 | 2005 | 98 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2006 | 197 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 55 | 0.050 |
Why?
|
| Indians, North American | 1 | 2004 | 75 | 0.050 |
Why?
|
| Poultry | 2 | 2014 | 13 | 0.050 |
Why?
|
| Keratosis, Seborrheic | 1 | 2003 | 1 | 0.050 |
Why?
|
| Handwriting | 1 | 2003 | 2 | 0.050 |
Why?
|
| Rural Population | 1 | 2005 | 216 | 0.050 |
Why?
|
| State Government | 1 | 2003 | 32 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2003 | 34 | 0.050 |
Why?
|
| Medicare Part A | 1 | 2003 | 5 | 0.050 |
Why?
|
| Medicare Part B | 1 | 2003 | 5 | 0.050 |
Why?
|
| Tonsillectomy | 1 | 2003 | 11 | 0.050 |
Why?
|
| Acrylic Resins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2002 | 50 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2002 | 25 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2002 | 14 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2002 | 4 | 0.050 |
Why?
|
| Photosensitivity Disorders | 1 | 2002 | 12 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2003 | 309 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2005 | 863 | 0.050 |
Why?
|
| New York City | 1 | 2002 | 12 | 0.050 |
Why?
|
| Maryland | 1 | 2002 | 27 | 0.050 |
Why?
|
| Capitation Fee | 1 | 2002 | 3 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2003 | 68 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 241 | 0.050 |
Why?
|
| California | 1 | 2002 | 61 | 0.050 |
Why?
|
| Tinea Versicolor | 1 | 2002 | 1 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2002 | 117 | 0.040 |
Why?
|
| Endpoint Determination | 2 | 2013 | 21 | 0.040 |
Why?
|
| Lasers | 1 | 2002 | 22 | 0.040 |
Why?
|
| Asian Americans | 1 | 2002 | 92 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2002 | 39 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 322 | 0.040 |
Why?
|
| Visual Perception | 1 | 2002 | 121 | 0.040 |
Why?
|
| Uncertainty | 1 | 2021 | 11 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2002 | 130 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 61 | 0.040 |
Why?
|
| Hypersensitivity | 2 | 2014 | 24 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 55 | 0.040 |
Why?
|
| Infectious Disease Medicine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Epidemiology | 1 | 2020 | 5 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 35 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 47 | 0.040 |
Why?
|
| Genitalia | 1 | 2020 | 9 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2007 | 14 | 0.040 |
Why?
|
| Decontamination | 1 | 2020 | 3 | 0.040 |
Why?
|
| Equipment Reuse | 1 | 2020 | 5 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 44 | 0.040 |
Why?
|
| Virus Inactivation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Telecommunications | 1 | 2020 | 6 | 0.040 |
Why?
|
| Masks | 1 | 2020 | 4 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 9 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 109 | 0.040 |
Why?
|
| Critical Care | 1 | 2020 | 108 | 0.040 |
Why?
|
| Iontophoresis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cholinergic Antagonists | 1 | 2019 | 10 | 0.040 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 3 | 0.040 |
Why?
|
| Skin Diseases, Viral | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sympathectomy | 1 | 2019 | 23 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 53 | 0.040 |
Why?
|
| Commerce | 1 | 2019 | 69 | 0.040 |
Why?
|
| Coal Tar | 2 | 2012 | 2 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 42 | 0.040 |
Why?
|
| New Jersey | 1 | 2018 | 9 | 0.030 |
Why?
|
| Half-Life | 1 | 2018 | 24 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2018 | 8 | 0.030 |
Why?
|
| Antipruritics | 1 | 2018 | 4 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 2018 | 15 | 0.030 |
Why?
|
| Anesthetics, Combined | 1 | 2018 | 6 | 0.030 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2018 | 26 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 5 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 9 | 0.030 |
Why?
|
| Knowledge Bases | 1 | 2017 | 4 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 28 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 38 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 45 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 156 | 0.030 |
Why?
|
| Smoking | 2 | 2013 | 505 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 90 | 0.030 |
Why?
|
| Agrochemicals | 2 | 2006 | 2 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 169 | 0.030 |
Why?
|
| Pharmacies | 1 | 2016 | 17 | 0.030 |
Why?
|
| Sebum | 1 | 2015 | 1 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nursing | 1 | 2015 | 1 | 0.030 |
Why?
|
| Blister | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 727 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 497 | 0.030 |
Why?
|
| Family | 1 | 2015 | 112 | 0.030 |
Why?
|
| Vidarabine | 1 | 2014 | 6 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 23 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 37 | 0.030 |
Why?
|
| Neck | 1 | 2014 | 32 | 0.030 |
Why?
|
| Drug Utilization Review | 2 | 2004 | 12 | 0.030 |
Why?
|
| Azathioprine | 1 | 2014 | 27 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2014 | 19 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 42 | 0.030 |
Why?
|
| Head | 1 | 2014 | 56 | 0.030 |
Why?
|
| Thiazolidines | 1 | 2014 | 2 | 0.030 |
Why?
|
| Actins | 1 | 2014 | 54 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 60 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 20 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 68 | 0.020 |
Why?
|
| Environment | 1 | 2013 | 47 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 136 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 112 | 0.020 |
Why?
|
| Air Conditioning | 1 | 2013 | 5 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 90 | 0.020 |
Why?
|
| Humidity | 1 | 2013 | 3 | 0.020 |
Why?
|
| Group Practice | 1 | 2013 | 3 | 0.020 |
Why?
|
| Private Practice | 1 | 2013 | 3 | 0.020 |
Why?
|
| Latin America | 1 | 2013 | 6 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 28 | 0.020 |
Why?
|
| Chickens | 1 | 2012 | 36 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 461 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 792 | 0.020 |
Why?
|
| Case Management | 1 | 2011 | 6 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 821 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 238 | 0.020 |
Why?
|
| Motivation | 1 | 2010 | 121 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2008 | 21 | 0.020 |
Why?
|
| Office Management | 1 | 2007 | 2 | 0.020 |
Why?
|
| Time Management | 1 | 2007 | 8 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 37 | 0.020 |
Why?
|
| Epidermis | 1 | 2007 | 29 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 13 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2007 | 16 | 0.020 |
Why?
|
| Minnesota | 1 | 2006 | 19 | 0.020 |
Why?
|
| Rural Health | 1 | 2007 | 22 | 0.020 |
Why?
|
| Rhode Island | 1 | 2006 | 5 | 0.020 |
Why?
|
| Insect Bites and Stings | 1 | 2006 | 2 | 0.020 |
Why?
|
| Plants | 1 | 2006 | 6 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 97 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 95 | 0.020 |
Why?
|
| Cinnamates | 1 | 2006 | 2 | 0.020 |
Why?
|
| Chalcones | 1 | 2006 | 3 | 0.020 |
Why?
|
| Propiophenones | 1 | 2006 | 4 | 0.020 |
Why?
|
| Workplace | 1 | 2006 | 37 | 0.010 |
Why?
|
| Water | 1 | 2006 | 65 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 83 | 0.010 |
Why?
|
| Sunburn | 1 | 2005 | 3 | 0.010 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 2 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 2005 | 9 | 0.010 |
Why?
|
| Dermabrasion | 1 | 2004 | 2 | 0.010 |
Why?
|
| Teratogens | 1 | 2004 | 2 | 0.010 |
Why?
|
| Writing | 1 | 2004 | 12 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 99 | 0.010 |
Why?
|
| Comprehension | 1 | 2003 | 18 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 892 | 0.010 |
Why?
|
| Dihydroxycholecalciferols | 1 | 2003 | 1 | 0.010 |
Why?
|
| Anthralin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2003 | 23 | 0.010 |
Why?
|
| Diaper Rash | 1 | 2002 | 1 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2002 | 95 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 2002 | 7 | 0.010 |
Why?
|